11:21 AM EST - Cipher Pharmaceuticals Inc. : Has acquired from Aclaris Therapeutics, Inc. the exclusive Canadian rights to distribute and commercialize A-101 40% topical solution. A-101 40% is an FDA-approved product indicated for the treatment of raised seborrheic keratoses (SKs), which are commonly occurring non-cancerous skin growths that affect more than nine million Canadian adults and can be an aesthetic skin concern. A-101 40% was approved by the FDA in December 2017 and is marketed by Aclaris in the U.S. under the tradename Eskata. Cipher Pharmaceuticals Inc.
shares T.CPH are trading up $0.02 at $4.03.
